The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
A study assessed an investigational three-drug combination—zanubrutinib, obinutuzumab, and sonrotoclax—in patients newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Among 15 patients, the treatment was generally well tolerated, with no deaths or discontinuations due to side effects. The most common side effects were low white blood cell counts, nausea, and infusion-related reactions. No laboratory or clinical tumor lysis syndrome (TLS) was observed during sonrotoclax ramp-up. All patients responded to treatment, and 60% achieved a complete response. Most reached deep remission (undetectable disease in the blood) within about three months. No disease progression was observed during the follow-up. These findings suggest the combination may be a promising treatment approach for newly diagnosed CLL/SLL.
